AnaptysBio, Inc. (ANAB)
56.28
-1.01
(-1.76%)
USD |
NASDAQ |
Aug 28, 16:00
56.18
-0.10
(-0.17%)
After-Hours: 20:00
AnaptysBio Shareholders Equity (Quarterly) : 12.75M for March 31, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 12.75M |
| December 31, 2025 | 37.21M |
| September 30, 2025 | -29.42M |
| June 30, 2025 | -44.73M |
| March 31, 2025 | 34.02M |
| December 31, 2024 | 70.87M |
| September 30, 2024 | 84.37M |
| June 30, 2024 | 9.879M |
| March 31, 2024 | 47.78M |
| December 31, 2023 | 88.10M |
| September 30, 2023 | 120.38M |
| June 30, 2023 | 148.45M |
| March 31, 2023 | 191.09M |
| December 31, 2022 | 262.10M |
| September 30, 2022 | 277.62M |
| June 30, 2022 | 304.31M |
| March 31, 2022 | 330.75M |
| December 31, 2021 | 356.43M |
| September 30, 2021 | 383.61M |
| June 30, 2021 | 385.73M |
| March 31, 2021 | 381.94M |
| December 31, 2020 | 396.73M |
| September 30, 2020 | 360.24M |
| Date | Value |
|---|---|
| June 30, 2020 | 381.44M |
| March 31, 2020 | 400.56M |
| December 31, 2019 | 405.01M |
| September 30, 2019 | 420.89M |
| June 30, 2019 | 448.42M |
| March 31, 2019 | 468.16M |
| December 31, 2018 | 486.36M |
| September 30, 2018 | 499.68M |
| June 30, 2018 | 284.98M |
| March 31, 2018 | 294.53M |
| December 31, 2017 | 307.58M |
| September 30, 2017 | 101.36M |
| June 30, 2017 | 109.18M |
| March 31, 2017 | 110.12M |
| December 31, 2016 | 39.27M |
| September 30, 2016 | 43.54M |
| June 30, 2016 | 44.40M |
| March 31, 2016 | 41.78M |
| December 31, 2015 | 42.34M |
| September 30, 2015 | 45.58M |
| June 30, 2015 | 5.853M |
| March 31, 2015 | 5.71M |
| December 31, 2014 | 5.993M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| 4D Molecular Therapeutics, Inc. | 407.66M |
| Design Therapeutics, Inc. | 201.86M |
| Inhibrx Biosciences, Inc. | -52.98M |
| Agenus, Inc. | -199.08M |
| Amgen, Inc. | 11.69B |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 329.68M |
| Total Liabilities (Quarterly) | 316.94M |
| Debt to Equity Ratio | 21.76 |
| Current Ratio | 7.580 |
| Net Debt Paydown Yield | 1.72% |